P/E ratio for Ascendis Pharma (ASND)
P/E ratio as of April 2025 (TTM): -12.5
According to Ascendis Pharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -12.4629. At the end of 2022 the company had a P/E ratio of -11.2.
P/E ratio history for Ascendis Pharma from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -11.2 | -32.16% |
| 2021 | -16.5 | -4.91% |
| 2020 | -17.3 | -34.07% |
| 2019 | -26.3 | 58.03% |
| 2018 | -16.6 | 75.98% |
| 2017 | -9.44 | 33.64% |
| 2016 | -7.07 | -41.95% |
| 2015 | -12.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -0.0050 | -99.96% | 🇺🇸 USA |
 | -0.7216 | -94.21% | 🇩🇪 Germany |
 | -2.77 | -77.81% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.